Balyasny Asset Management LLC Clovis Oncology, Inc. Transaction History

Balyasny Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.63 - $2.96 $9,621 - $45,205	15,272 Added 132.01%	26,841 $48,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $65,827 - $112,103	11,569 New	11,569 $78,000
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $1.54 Million - $6.03 Million	-392,919 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $399,415 - $800,390	-31,180 Reduced 7.35%	392,919 $5.84 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $730,788 - $1.25 Million	41,381 Added 10.81%	424,099 $10.5 Million
Q4 2018 Feb 14, 2019	BUY	$11.63 - $32.67 $914,722 - $2.57 Million	78,652 Added 25.87%	382,718 $6.87 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $2.24 Million - $3.77 Million	-76,247 Reduced 20.05%	304,066 $8.93 Million
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $3.74 Million - $5.54 Million	-88,853 Reduced 18.94%	380,313 $17.3 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $7.81 Million - $10.6 Million	155,921 Added 49.78%	469,166 $24.8 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $10.8 Million - $15.8 Million	-186,443 Reduced 37.31%	313,245 $21.3 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $33.6 Million - $42.4 Million	499,688	499,688 $41.2 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.